Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Interim Analysis Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial

Authors :: Mesa, Ruben A.
Hoffman, Ronald
Kosiorek, Heidi E.
Prchal, Josef T.
Harrison, Claire N.
McMullin, Mary Frances
Yacoub, Abdulraheem
Rambaldi, Alessandro
Berenzon, Dmitriy
Vannucchi, Alessandro M.
Ewing, Joanne C
O'Connell, Casey L
Kiladjian, Jean-Jacques
Mead, Adam
Winton, Elliott F.
Leibowitz, David S.
De Stefano, Valerio
Arcasoy, Murat O.
Kessler, Craig M.
Catchatorian, Rosalind
Rondelli, Damiano
Silver, Richard T.
Ritchie, Ellen K.
Nagler, Arnon
Kremyanskaya, Marina
Schlenk, Richard F.
Weinberg, Rona Singer
Salama, Mohamed E
Tognoni, Gianni
Prosperini, Giuseppe
Di Lelio, Alessandra
Serone, Eliseo
Marfisi, Lorenzo
Orellana, Alicia
Barbui, Tiziano
Dueck, Amylou C.
Mascarenhas, John O.
Source :: Blood; January 2016, Vol. 128 Issue: 22 p4271-4271, 1p
Publication Year :: 2016
Abstract: Background:Patients (pts) with polycythemia vera (PV) and essential thrombocythemia (ET) suffer from disease related events linked to risk of vascular events, splenomegaly, progression to myelofibrosis/acute leukemia, and disease related symptoms arising from both elevated cytokines and issues of vascular flow. Impact of front line therapy on ET/PV symptoms has not been reported in a systematic fashion.

Full Text Access

Tools